Distribution of ganciclovir in the porcine central nervous system
- PMID: 40116478
- PMCID: PMC12057358
- DOI: 10.1128/aac.01815-24
Distribution of ganciclovir in the porcine central nervous system
Abstract
Ganciclovir is often used compassionately for encephalitis due to cytomegalovirus (CMV) and human herpes virus 6b (HHV-6b). Ganciclovir pharmacokinetic studies in the central nervous system (CNS) generally rely on single measurements in the cerebrospinal fluid (CSF) or homogenized brain tissue. Therefore the objective was to compare brain extracellular fluid (ECF) concentrations of ganciclovir with plasma and CSF concentrations in a porcine model, using microdialysis during a 24 h period. Six Danish landrace pigs (female, age 4 months, 31-37 kg) received two weight-adjusted intravenous doses of ganciclovir. Unbound ganciclovir concentrations were determined by microdialysis over 24 h in five compartments: CSF (lateral ventricle, cisterna magna, and lumbar) and brain ECF (cortical and subcortical). Data were compared with paired plasma samples. Ganciclovir concentrations >IC50 for CMV (1.6 µg/mL) were achieved in all compartments. Concentrations >IC90 for CMV (8.3 µg/mL) were only achieved in plasma and the lumbar CSF compartment. The concentration time curves indicated higher lumbar and cisternal CSF concentrations than ECF concentrations. The ECF compartments achieved greater maximum concentration (Cmax), area under the concentration time curve (AUC), and time >IC50 after the second dose, and an accumulation ratio (Rac) >1. The greater Cmax, AUC, time >IC50, and Rac >1 in the ECF compartments with repeated dosages suggest that therapeutic concentrations may be achieved during long-term treatment. A higher loading dose might be warranted to improve early viral inhibition.
Keywords: CNS; animal models; antiviral agents; antiviral pharmacology; ganciclovir; microdialysis; pharmacokinetics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Distribution of acyclovir in central nervous system compartments: a porcine pharmacokinetic model.Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0181124. doi: 10.1128/aac.01811-24. Epub 2025 Jul 9. Antimicrob Agents Chemother. 2025. PMID: 40631963 Free PMC article.
-
Continuous evaluation of single-dose moxifloxacin concentrations in brain extracellular fluid, cerebrospinal fluid, and plasma: a novel porcine model.J Antimicrob Chemother. 2024 Jun 3;79(6):1313-1319. doi: 10.1093/jac/dkae098. J Antimicrob Chemother. 2024. PMID: 38573940
-
Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?Clin Microbiol Infect. 2025 Apr;31(4):534-541. doi: 10.1016/j.cmi.2024.12.008. Epub 2024 Dec 13. Clin Microbiol Infect. 2025. PMID: 39675474 Review.
-
Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates.Cancer Chemother Pharmacol. 1999;43(5):415-8. doi: 10.1007/s002800050916. Cancer Chemother Pharmacol. 1999. PMID: 10100598
-
The entry of antiviral and antiretroviral drugs into the central nervous system.J Neurovirol. 1997 Dec;3(6):387-400. doi: 10.3109/13550289709031185. J Neurovirol. 1997. PMID: 9475111 Review.
References
-
- Bolokadze N, Gabunia P, Ezugbaia M, Gatserelia L, Khechiashvili G. 2008. Neurological complications in patients with HIV/AIDS. Georgian Med News 2008:34–38. - PubMed
-
- Ljungman P, Wang FZ, Clark DA, Emery VC, Remberger M, Ringdén O, Linde A. 2000. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 111:774–781. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous